LINC: The LUCAS device failed to demonstrate benefit in cardiac arrest patients.

Each year between 300,000 and 400,000 people suffer an out-of-hospital heart attack in Europe. Only between 5% and 7% of these patients survive and are discharged. Cardiopulmonary resuscitation guidelines recommend manual chest compression with few intervals wherever possible. Manual chest compression only achieves between 20 and 30% of normal blood flow and is difficult to maintain for long periods.

Mechanical chest compression with the LUCAS device demonstrated an increased blood flow in experimental studies. The goal of the study was to show higher survival rate with the LUCAS device vs manual chest compression in out-of-hospital cardiac arrest patients.

1300 patients were included and subjected to resuscitation with the LUCAS device and 1289 with traditional resuscitation. The results showed that survival at 4 hours was similar (23.6% vs 23.7%) as was neurological evolution at 1 and 6 months.

Conclusion: 

Mechanical compression with the LUCAS device in combination with defibrillation during compression was not shown to be superior in survival rate at 4 hours or subsequent neurological recovery.

Sten%20Rubertsson_slides
Sten Rubertsson
2013-09-02

Original title: LINC—A multicenter randomized trial comparing a mechanical CPR algorithm using LUCAS vs manual CPR in out-of-hospital cardiac arrest patients.

 

More articles by this author

INTIME: Home monitoring of severe heart failure patients gives promising results.

Rehospitalization or death due to worsening heart failure is often preceded by changes in clinical parameters, weight or arrhythmias. The home monitoring device has...

DECAAF: Pre ablation magnetic resonance in patients with atrial fibrillation is capable of detecting the degree of fibrosis and predicting the success of...

260 patients with atrial fibrillation were included who underwent nuclear magnetic resonance 30 days before ablation and 90 days following. The patients were classified...

PRAGUE 14: Anti-thrombotic therapy before non-cardiac surgery may be associated with a higher incidence of bleeding.

The majority of coronary patients are under anti-thrombotic therapy and its interruption may increase cardiovascular risk, while on the other hand, continuation during a...

PARIS: Interruption of dual antiplatelet treatment can be safe depending on the clinical context and treatment time

The cessation of dual antiplatelet treatment increased the risk of post coronary intervention adverse events. It is unclear whether the risk varies through time...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....